Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
Jacinth Wing-Sum Cheu,David Kung-Chun Chiu,Kenneth Kin-Leung Kwan,Chunxue Yang,Vincent Wai-Hin Yuen,Chi Ching Goh,Noreen Nog-Qin Chui,Wei Shen,Cheuk-Ting Law,Qidong Li,Misty Shuo Zhang,Macus Hao-Ran Bao,Bowie Po-Yee Wong,Cerise Yuen-Ki Chan,Cindy Xinqi Liu,Grace Fu-Wan Sit,Zher Yee Ooi,Haijing Deng,Aki Pui-Wah Tse,Irene Oi-Lin Ng,Carmen Chak-Lui Wong
DOI: https://doi.org/10.1126/sciadv.ade5111
IF: 13.6
2023-05-07
Science Advances
Abstract:Hypoxia-induced adenosine creates an immunosuppressive tumor microenvironment (TME) and dampens the efficacy of immune checkpoint inhibitors (ICIs). We found that hypoxia-inducible factor 1 (HIF-1) orchestrates adenosine efflux through two steps in hepatocellular carcinoma (HCC). First, HIF-1 activates transcriptional repressor MXI1, which inhibits adenosine kinase (ADK), resulting in the failure of adenosine phosphorylation to adenosine monophosphate. This leads to adenosine accumulation in hypoxic cancer cells. Second, HIF-1 transcriptionally activates equilibrative nucleoside transporter 4, pumping adenosine into the interstitial space of HCC, elevating extracellular adenosine levels. Multiple in vitro assays demonstrated the immunosuppressive role of adenosine on T cells and myeloid cells. Knockout of ADK in vivo skewed intratumoral immune cells to protumorigenic and promoted tumor progression. Therapeutically, combination treatment of adenosine receptor antagonists and anti–PD-1 prolonged survival of HCC-bearing mice. We illustrated the dual role of hypoxia in establishing an adenosine-mediated immunosuppressive TME and offered a potential therapeutic approach that synergizes with ICIs in HCC.
multidisciplinary sciences